Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
Enrolled patients received a single priming dose of 300 mg/m2 Cy intravenously on cycle 1, day 1 (C1D1). The next day (C1D2), patients received 200 mg pembrolizumab intravenously. Pembrolizumab was given every 3 weeks until either progressive disease (PD) was seen or the patient suffered significant toxicity, at which point they discontinued protocol-directed therapy.
Copyright and License information: ©2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
